PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2 – Small Caps

Further pre-clinical testing of PharmAusts (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 the virus causing the global COVID-19 pandemic.
Following positive earlier results in both primate and non-primate cell cultures, Leiden University Medical Centre has carried out more tests and generated data indicating both MPL and MPLS demonstrate antiviral activity in non-human primates.
This paves…

Click here to view the original article.